In a recent trial of patients with advanced non–small-cell lung cancer, liquid biopsy led to faster molecular results and shortened time to treatment. Read More ›

CodeBreak 200 phase 3 trial results demonstrated that sotorasib achieved a more robust survival benefit versus docetaxel in patients with advanced non–small-cell lung cancer harboring KRAS G12C mutation. Read More ›

Biomarker testing is the standard of care in advanced non–small-cell lung cancer, but the rate of patients receiving test results prior to initiating treatment is low. Read More ›

Study finds that frequencies of mutations commonly found in patients with non–small-cell lung cancer vary among members of 3 racial groups. Read More ›

Study of patients with lung adenocarcinoma found that patients with KRAS G12C mutation and high PD-L1 expression benefit more from immunotherapy compared with patients with other KRAS mutations. Read More ›

Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with  Immune Checkpoint Inhibitors

A study in patients with KRAS G12C-mutated non–small-cell lung cancer with brain metastases found adagrasib to demonstrate intracranial activity while being well tolerated. Read More ›

Study finds circulating tumor DNA reveals disease recurrence before radiographic evidence in patients with non–small-cell lung cancer. Read More ›

Recent study showed that KRAS mutation in patients with non–small-cell lung cancer predicted superior response to first-line immunotherapy. Read More ›

Real-world analysis of mutations in non–small-cell lung cancer showed similar frequencies of common KRAS and EGFR variants in Black and White Americans, but higher EGFR G719S variant was seen in Black Americans. Read More ›

Page 1 of 374

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: